These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 30870)

  • 1. [Beta-blocking and beta-stimulation in left ventricular failure].
    Waagstein F
    Lakartidningen; 1978 Nov; 75(47):4376-81. PubMed ID: 30870
    [No Abstract]   [Full Text] [Related]  

  • 2. [Assessment of chronotropic effect and arrhythmogenesis on beta 1-partial agonist (Xamoterol) in chronic heart failure].
    Fukuda K; Handa S; Ogawa S; Nakamura Y; Kawamura Y
    Kokyu To Junkan; 1988 Nov; 36(11):1227-33. PubMed ID: 2907820
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparison of the hemodynamic effects in man of 2 beta-blockaders: propranolol and practolol].
    Ambrosioni E; Bracchetti D; Russo F; Catizone L; Perri G; Magnani B
    Boll Soc Ital Cardiol; 1972; 17(2):91-101. PubMed ID: 4403643
    [No Abstract]   [Full Text] [Related]  

  • 4. [Hemodynamic studies on the beta receptor blockader Kö 592 under rest and under exertion].
    Deibert K; Steim H; Heinrich K; Siller K
    Med Klin; 1972 Jun; 67(24):845-9. PubMed ID: 4403610
    [No Abstract]   [Full Text] [Related]  

  • 5. Beta-adrenergic blocking therapy in hypertension: selection of patients.
    Frohlich ED; Tarazi RC; Dustan HP
    Int Z Klin Pharmakol Ther Toxikol; 1970 Dec; 4(1):151-6. PubMed ID: 4395481
    [No Abstract]   [Full Text] [Related]  

  • 6. [Adrenergic betareceptors and cardiac insufficiency].
    Weber S; Cabanes L; Guérin F
    Arch Mal Coeur Vaiss; 1990 Nov; 83(13):1957-61. PubMed ID: 1980187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency].
    Richaud M; Lechat P; Komajda M; Landault C; Fournier P; Fraysse JB; Grosgogeat Y
    Arch Mal Coeur Vaiss; 1990 Feb; 83(2):247-52. PubMed ID: 1968739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-receptor-active agents: role of partial agonists in patients with heart failure.
    Franciosa JA
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S44-7. PubMed ID: 2478809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Heart failure: beta-stimulant or beta-blocker?].
    Weber S; Cabanes L; Lanouar K; Degeorges M
    Rev Prat; 1988 Mar; 38(9):542-9. PubMed ID: 2895956
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of adrenergic beta receptor blocking agents on cardiac output.
    Madan BR; Gupta RS
    Indian Heart J; 1970 Apr; 22(2):70-2. PubMed ID: 4400289
    [No Abstract]   [Full Text] [Related]  

  • 11. Haemodynamic changes in patients with coronary heart disease after beta-adrenergic blockade with propranolol.
    Bürgin D
    Int Z Klin Pharmakol Ther Toxikol; 1970 Oct; 4(4):365-70. PubMed ID: 4395489
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of immediate haemodynamic effects of three beta-adrenergic blocking agents.
    Rivier JL; Nissiotis E; Jaeger M
    Postgrad Med J; 1970 Nov; ():Suppl:44-9. PubMed ID: 4395457
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathophysiological mechanisms underlying the effects of beta-adrenergic agonists and antagonists on functional capacity and survival in chronic heart failure.
    Packer M
    Circulation; 1990 Aug; 82(2 Suppl):I77-88. PubMed ID: 1973643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional improvement in heart failure patients treated with beta-blockers is associated with a decline of cytokine levels.
    Mayer B; Holmer SR; Hengstenberg C; Lieb W; Pfeifer M; Schunkert H
    Int J Cardiol; 2005 Aug; 103(2):182-6. PubMed ID: 16080978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity of beta-adrenoceptor agonists and antagonists in asthmatics.
    Löfdahl CG
    Eur J Respir Dis Suppl; 1982; 120():1-53. PubMed ID: 6125404
    [No Abstract]   [Full Text] [Related]  

  • 16. Circulatory effects of oxprenolol, a new beta-adrenergic blocking agent.
    Reale A; Motolese M; Imhof P
    Int Z Klin Pharmakol Ther Toxikol; 1970 Jul; 3(3):288-93. PubMed ID: 4394124
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular consequences of beta-agonist tocolysis: an echocardiographic study.
    Finley J; Katz M; Rojas-Perez M; Roberts JM; Creasy RK; Schiller NB
    Obstet Gynecol; 1984 Dec; 64(6):787-91. PubMed ID: 6150456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists.
    Packer M
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S38-43. PubMed ID: 2478808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catecholamines and heart function in heart transplant patients: effects of beta1- versus nonselective beta-blockade.
    Leenen FH; Davies RA; Fourney A
    Clin Pharmacol Ther; 1998 Nov; 64(5):522-35. PubMed ID: 9834044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of diastolic function and exercise capacity in ischemic left ventricular dysfunction. Role of beta-agonists and beta-antagonists.
    Pouleur H; Hanet C; Rousseau MF; van Eyll C
    Circulation; 1990 Aug; 82(2 Suppl):I89-96. PubMed ID: 1973644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.